Literature DB >> 30393616

Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer.

Joseph Carmicheal1, Sukhwinder Kaur1, Surinder K Batra1, Apar Kishor Ganti2.   

Abstract

Entities:  

Year:  2018        PMID： 30393616      PMCID： PMC6193924          DOI： 10.21037/tlcr.2018.09.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

2.  Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.

Authors:  Jinyao Wang; Yizhe Wang; Chunlei Zheng; Kezuo Hou; Tieqiong Zhang; Xiujuan Qu; Yunpeng Liu; Jian Kang; Xuejun Hu; Xiaofang Che
Journal:  Cell Biol Int       Date:  2018-06-20       Impact factor: 3.612

Review 3.  Transcription factor decoy technology: A therapeutic update.

Authors:  Markus Hecker; Andreas H Wagner
Journal:  Biochem Pharmacol       Date:  2017-06-19       Impact factor: 5.858

4.  Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3.

Authors:  Karni Schlessinger; David E Levy
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 5.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

6.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Authors:  Benjamin J Solomon; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Yiyun Tang; Keith D Wilner; Fiona Blackhall; Tony S Mok
Journal:  J Clin Oncol       Date:  2018-05-16       Impact factor: 44.544

Review 8.  Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

Authors:  Mark Sanford; Lesley J Scott
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

9.  Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Authors:  Michaël Duruisseaux; Benjamin Besse; Jacques Cadranel; Maurice Pérol; Bertrand Mennecier; Laurence Bigay-Game; Renaud Descourt; Eric Dansin; Clarisse Audigier-Valette; Lionel Moreau; José Hureaux; Remi Veillon; Josiane Otto; Anne Madroszyk-Flandin; Alexis Cortot; François Guichard; Pascaline Boudou-Rouquette; Alexandra Langlais; Pascale Missy; Franck Morin; Denis Moro-Sibilot
Journal:  Oncotarget       Date:  2017-03-28

10.  Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

Authors:  S Takemoto; K Ushijima; K Kawano; T Yamaguchi; A Terada; N Fujiyoshi; S Nishio; N Tsuda; M Ijichi; T Kakuma; M Kage; D Hori; T Kamura
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640
View more
  1 in total

Review 1.  STAT3 pathway in cancers: Past, present, and future.

Authors:  Han-Qi Wang; Qi-Wen Man; Fang-Yi Huo; Xin Gao; Hao Lin; Su-Ran Li; Jing Wang; Fu-Chuan Su; Lulu Cai; Yi Shi; Bing Liu; Lin-Lin Bu
Journal:  MedComm (2020)       Date:  2022-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.